Status:
COMPLETED
Quality of Life of Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Lead Sponsor:
M.D. Anderson Cancer Center
Conditions:
Acute Myelogenous Leukemia
Myelodysplastic Syndrome
Eligibility:
All Genders
18+ years
Brief Summary
Primary Objectives: * To compare the neuropsychiatric (NP) and neurocognitive (NC) symptoms and assess the quality of life (QOL) in older patients (age \> 18) with acute myelogenous leukemia (AML) or...
Detailed Description
You will participate in a series of neurocognitive tests. For these tests, you will be asked to complete certain tasks that require the use of your hands, eyes, and ears. The neurocognitive testing wi...
Eligibility Criteria
Inclusion
- Patients with newly diagnosed AML or MDS. Patients who fail an MDS/AML therapy and receive other therapies may be asked to continue participation in this neurocognitive study.
- Patients who are 18 years of age or older.
- Patients who are seen in the MDACC adult Leukemia clinic. Patients who do not enroll onto therapy protocols are also eligible.
- Patients must sign the informed consent.
Exclusion
- 1\) Not applicable
Key Trial Info
Start Date :
April 1 2004
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2009
Estimated Enrollment :
104 Patients enrolled
Trial Details
Trial ID
NCT00459524
Start Date
April 1 2004
End Date
March 1 2009
Last Update
August 1 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
U.T.M.D. Anderson Cancer Center
Houston, Texas, United States, 77030